AVALO THERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
AVALO THERAPEUTICS, INC. (AVTX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$7.99 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-11-07
- AVALO THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$6.19K.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $0.00.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$1.80K.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$9.24K.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$34.88K.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$19.98K.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$19.50K.
- AVALO THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$29.27K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-09-30 | -$6.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$6.19K derived: sum of 2 quarters · filed 2017-11-07 | -$7.99K 10-Q · filed 2017-11-07 | -$17.23K derived: sum of 4 quarters · filed 2017-11-07 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$1.80K 10-Q · filed 2017-08-14 | -$11.04K derived: sum of 3 quarters · filed 2017-08-14 | -$17.53K derived: sum of 4 quarters · filed 2017-11-07 |
| 2017-03-31 | -$1.80K 10-Q · filed 2017-05-09 | -$11.04K derived: sum of 2 quarters · filed 2017-05-09 | -$17.53K derived: sum of 3 quarters · filed 2017-11-07 | -$27.79K derived: sum of 4 quarters · filed 2017-11-07 |
| 2016-12-31 | -$9.24K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | -$15.73K derived: sum of 2 quarters · filed 2017-11-07 | -$25.98K derived: sum of 3 quarters · filed 2017-11-07 | -$34.88K 10-K · filed 2017-03-14 |
| 2016-09-30 | -$6.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$16.75K derived: sum of 2 quarters · filed 2017-11-07 | -$25.65K 10-Q · filed 2017-11-07 | -$25.65K derived: sum of 4 quarters · filed 2017-11-07 |
| 2016-06-30 | -$10.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$19.16K 10-Q · filed 2017-08-14 | -$19.16K derived: sum of 3 quarters · filed 2017-08-14 | |
| 2016-03-31 | -$8.90K 10-Q · filed 2017-05-09 | -$8.90K derived: sum of 2 quarters · filed 2017-05-09 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | -$19.98K 10-K · filed 2017-03-14 | ||
| 2015-09-30 | -$19.98K 10-Q · filed 2016-11-08 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | -$19.50K 10-K · filed 2017-03-14 | ||
| 2014-09-30 | -$19.50K 10-Q · filed 2015-11-13 | |||
| 2013-12-31 | -$29.27K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |